SEATTLE (PRWEB) May 23, 2018
AngelMD, a platform that connects medial startups with doctors that provide guidance and investors that provide funding, today announced that a group of its physician and investor members has completed the latest funding round for Sensulin, LLC.
“Sensulin is excited to work with AngelMD again, in this Series B round. We could not have raised our Series A without them, and they helped us build momentum toward this new round, which will enable us to conduct first-in-human studies,” said Mike Moradi, CEO of Sensulin.
Sensulin’s work is focused on developing a glucose-responsive insulin to treat both Type 1 and 2 diabetes. Diabetes is overwhelmingly prevalent in America, with over 100 million americans having some form of the disease. 1.5 million Americans are diagnosed with Type 2 diabetes every year, and though less common, there are still 1.25 million Americans living with Type 1 diabetes. Since patients with Type 1 diabetes do not have a pancreas which produces regular levels of insulin, typical management includes 4-8 insulin injections a day.
Sensulin’s Agglomerated Vesicle Technology (AVT) makes the insulin stimulus-responsive, meaning that the amount of insulin released is proportional to a patient’s blood sugar, and the company aims to reduce those eight injections a day to a single daily dose.
Though Sensulin is focused on developing its insulin product, AVT is first and foremost a drug delivery system, and is not specific to insulin. The tech uses a series of liposomes which are “glued together” by a molecule that responds to a specific stimulus. This can be used to encapsulate various drugs triggered by various stimuli (inflammation, low blood oxygen, etc.), providing the opportunity for future innovative treatments. The technology has been proven to work as an injectable or inhalable formulation.
“We met Mike Moradi, Sensulin's CEO, at the first AngelMD event we hosted at our home,” said Dr. Wendy Whittington, Regional Medical Director at AngelMD. “I was immediately struck by the passion he brings to his work and his quiet yet competent way of articulating the science. Diabetes is such a huge problem worldwide and one that needs more focus and innovation. I also loved that the science behind Sensulin can be translated to other drugs and therefore utilized in ways we haven't yet considered.”
Sensulin will use the funds to push forward its research and development and conduct its first-in-human studies for the glucose-responsive insulin.
AngelMD is an investment and networking platform connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined AngelMD to help source, evaluate and advise companies in biotechnology, medical device, and healthcare technology. For more information, visit http://www.angelmd.co.
Sensulin is a biotechnology company, developing a next-generation insulin for diabetes. The company's glucose-responsive insulin may provide a patient’s entire daily insulin need via a single dose. Sensulin aims to make basal and mealtime insulin obsolete, reduce the need for glucose monitoring, greatly improve the standard of care, and solve one of the largest unmet medical needs in all of healthcare. For both Type 1 (T1D) and Type 2 Diabetes (T2D) patients, Sensulin may reduce the long-term complications associated with diabetes, and most importantly, give patients a chance at a normal life. See http://www.sensulin.com.